Literature DB >> 24092816

Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension?

Daniel I Simon1, Norman M Simon.   

Abstract

Entities:  

Keywords:  Editorials; arteriosclerosis; hypertension; plasminogen activator inhibitor 1; plasminogen activators; protease inhibitors

Mesh：

Substances：

Year:  2013        PMID： 24092816      PMCID： PMC3997105          DOI： 10.1161/CIRCULATIONAHA.113.006321

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  24 in total

1.  Nonfibrinolytic functions of plasminogen.

Authors:  V A Ploplis; F J Castellino
Journal:  Methods       Date:  2000-06       Impact factor: 3.608

Review 2.  Pulse pressure, arterial stiffness, and drug treatment of hypertension.

Authors:  L M Van Bortel; H A Struijker-Boudier; M E Safar
Journal:  Hypertension       Date:  2001-10       Impact factor: 10.190

Review 3.  Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases.

Authors:  Michel E Safar; Bernard I Levy; Harry Struijker-Boudier
Journal:  Circulation       Date:  2003-06-10       Impact factor: 29.690

Review 4.  Plasminogen activators, tissue degradation, and cancer.

Authors:  K Danø; P A Andreasen; J Grøndahl-Hansen; P Kristensen; L S Nielsen; L Skriver
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

5.  Macrophage fibrinolytic activity: identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor.

Authors:  H A Chapman; Z Vavrin; J B Hibbs
Journal:  Cell       Date:  1982-03       Impact factor: 41.582

6.  Human plasmin.

Authors:  K C Robbins; L Summaria; R C Wohl
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

7.  Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli.

Authors:  D Pennica; W E Holmes; W J Kohr; R N Harkins; G A Vehar; C A Ward; W F Bennett; E Yelverton; P H Seeburg; H L Heyneker; D V Goeddel; D Collen
Journal:  Nature       Date:  1983-01-20       Impact factor: 49.962

8.  The complete amino acid sequence of low molecular mass urokinase from human urine.

Authors:  G J Steffens; W A Günzler; F Otting; E Frankus; L Flohé
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1982-09

9.  Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor.

Authors:  B Wiman; J Chmielewska; M Rånby
Journal:  J Biol Chem       Date:  1984-03-25       Impact factor: 5.157

10.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272
View more
  5 in total

1.  Associations of snoring frequency with blood pressure among the lean Japanese population: the Toon Health Study.

Authors:  Ryoji Goto; Takeshi Tanigawa; Koutatsu Maruyama; Kiyohide Tomooka; Eri Eguchi; Haruhiko Osawa; Isao Saito
Journal:  J Hum Hypertens       Date:  2019-01-08       Impact factor: 3.012

2.  PAI-1 Inhibition - Another Therapeutic Option for Cardiovascular Protection.

Authors:  Monica Mariana Baluta; Marius Marcian Vintila
Journal:  Maedica (Buchar)       Date:  2015-06

3.  Ets-1 upregulation mediates angiotensin II-related cardiac fibrosis.

Authors:  Guanghua Hao; Zhenhua Han; Zhe Meng; Jin Wei; Dengfeng Gao; Hong Zhang; Nanping Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.

Authors:  Tessa M Simone; Stephen P Higgins; Craig E Higgins; Michelle R Lennartz; Paul J Higgins
Journal:  J Mol Genet Med       Date:  2014-10

5.  Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression.

Authors:  Laura Gonzalez-Calero; Marta Martin-Lorenzo; Fernando de la Cuesta; Aroa S Maroto; Montserrat Baldan-Martin; Gema Ruiz-Hurtado; Helena Pulido-Olmo; Julian Segura; Maria G Barderas; Luis M Ruilope; Fernando Vivanco; Gloria Alvarez-Llamas
Journal:  Cardiovasc Diabetol       Date:  2016-01-16       Impact factor: 9.951
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.